Kornimate/medical-research-clean huggingface dataset:
effects of berries and vegetables on cardiometabolic risk markers and cognitive functions

Conditions: Metabolic Syndrome; Inflammation; Aging; Fermentation

Summary: the purpose of the study is to study the potential anti-inflammatory- and metabolic effects of polyphenols and dietary fibres in a product based on a mixture of several swedish berries and vegetables that is known to have high amounts of polyphenols and other anit-oxidants. in addition the purpose is to investigate the effects on cognitive functions of the berry product.

the metabolic syndrome (mets) includes a cluster of dysfunctions that identifies subjects at risk of developing type-2 diabetes and cardiovascular disease (cvd). a key feature appears to be chronic increased inflammation and activation of the innate system. consequently, increased low-grade inflammation has been connected to adverse effects on insulin sensitivity, glucose- and lipid metabolism, and blood pressure, and circulating markers of inflammation such as il-6. a growing body of evidence also link low-grade inflammation to poorer cognitive functioning. type 2 diabetes, mets, and glucose intolerance are increasingly being associated with impaired cognition. dietary patterns which promote sub-clinical inflammation are increasingly being considered predictive of future risk of cvd and type-2 diabetes. there is a growing insight regarding the role of the colonic micro flora in metabolic regulation and development of low-grade inflammation and obesity. the metabolic cross talk between the colon and peripheral tissues, especially adipose tissue, has been suggested to be regulated through colonic fermentation of indigestible carbohydrates e.g. dietary fibres (df) and resistant starch. in addition, epidemiological data shows that a high consumption of vegetables and fruits is associated with a lowered risk of cancer and cardiovascular disease, which may be due to the high concentrations of polyphenols or other anti-oxidants that are found in such foods. in addition vegetables and berries are rich in dietary fibres with the potential to beneficially modulate the gut micro flora which may have implication on metabolic risk factors. in the presently described project it is hypothesized that 5 w daily consumption of a food product containing berries and vegetables can improve metabolic risk variables and cognitive functions. the purpose is therefore to study the potential anti-inflammatory- and metabolic effects, and prebiotic properties, of a food product based on a mixture of several swedish berries and vegetables that is known to be rich in dietary fibres, polyphenols and other anti-oxidants. in addition the purpose is to investigate the effects on cognitive functions of the food product.

Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * fasting plasma glucose \>6.1 * known cognitive decline * other medications than for treatment of hypertension or hypothyroidism known gastro- intestinal problems

Keywords: dietary prevention cognitive performance metabolic syndrome colonic fermentation sub clinical inflammation cognition and metabolism
stimulation change effects on quantitative sensory testing in neuromodulation patients

Conditions: Chronic Pain

Summary: this study is designed to evaluate the effectiveness of two types of spinal cord stimulation programming types, in comparison to each other as well as patient baseline data.

in this study patients have been implanted with an abbott spinal cord stimulator capable of delivering both tonic (continuous) stimulation as well as burst (intermittent) stimulation. patients are programmed to be in both stimulation modes for a study period of 4 weeks, after which their pain symptoms are evaluated on a variety of surveys: mcgill pain questionnaire (mpq), oswestry disability index (odi), beck depression inventory (bdi), pain catastrophizing scale (pcs), epworth sleepiness scale (ess), insomnia severity index (isi), numerical rating scale (nrs) and global improvement. they also undergo quantitative sensory testing (qst), where thermal, mechanical, vibration and pressure stimuli are applied to the patient and detection limits are documented.

Eligibility criteria:
inclusion criteria: 1. albany medical center neurosurgery patients with chronic leg and/or back pain, that have, or are going to have, spinal cord stimulator implantation. 2. patients are \>/= 18 years old at the time of enrollment. 3. patients must be: fluent in english; mentally competent; able to read and answer questionnaires; complete pain assessments; and give informed consent. exclusion criteria: 1. patients less than 18 years old. 2. patients unable or unwilling to: read and answer questionnaires; complete pain assessments; and give informed consent.
the results of total hip arthroplasty in crowe type 4 hips.

Conditions: The Results of Total Hip Arthroplasty in Crowe Type 4 Dysplastic Hips

Summary: total hip arthroplasty (tha) performed for developmental dysplasia of the hip (ddh) is a technically difficult procedure with a high complication rate, especially in the presence of completely dislocated hips. this study aimed to evaluate the results of at least 10 years of follow-up results of cementless, ceramic-on-ceramic (coc) total hip arthroplasty performed with transverse subtrochanteric osteotomy in crowe type 4 hips.

we reviewed retrospectively 67 hips of 50 patients which underwent coc, cementless tha with transverse subtrochanteric osteotomy between 2008 and 2011. clinical and radiological data of the hips were examined. clinical results were evaluated using the harris hip score (hhs) and the western ontario and mcmaster universities osteoarthritis index (womac).

Eligibility criteria:
inclusion criteria: crowe type 4 developmental dysplasia of the hip exclusion criteria: primary coxarthrosis

Keywords: developmental dysplasia of the hip, total hip arthroplasty, transverse subtrochanteric shortening osteotomy, ceramic on ceramic, cementless.
project to improve communication about serious illness - pilot study

Conditions: Malignant Neoplasm; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Disease Chronic; Congestive Heart Failure; Liver Failures, Chronic; Renal Insufficiency, Chronic; Dementia; Diabetes Complications; Peripheral Vascular Disease; Frail Elderly

Summary: this two-year pilot study will test whether a one-page "jumpstart form" will affect goals-of-care discussions in the hospital. this form will be provided to clinicians and will include patient-specific information about preferences for goals-of-care communication and for care, as well as tips to improve this communication. jumpstart forms will also be provided to patients or, if they are unable to communicate, their surrogates/family members. the information on the form will be obtained from questionnaires. the form is tailored to help patients and surrogates talk with clinicians about goals of care. this study is based on a successful application of jumpstart form in the outpatient clinic setting.


Eligibility criteria:
inclusion criteria, patients: meeting criteria for serious illness (encompassing multiple acute and chronic illnesses) including: * those used by the dartmouth atlas to study end-of-life care in the us: malignant cancer/leukemia, chronic pulmonary disease, coronary artery disease, congestive heart failure, chronic liver disease, chronic renal disease, dementia, diabetes with end-organ damage, and peripheral vascular disease. * patients over age 65 with markers of frailty: albumin level \<3.0 within 48 hours of admission and weight loss of ≥10 pounds in the past year. * hospitalized patients over age 80. * english-speaking exclusion criteria, patients: * unable to complete informed consent procedures and do not have a legal next of kin * restricted information status (e.g. prisoners) * pregnant inclusion criteria, surrogates: * involved in the care of an eligible patient as the legal next-of-kin * english-speaking exclusion criteria, surrogates: * unable to complete informed consent procedures
endoscopic full-thickness plication for the treatment of gerd: long-term multicenter results

Conditions: Gastroesophageal Reflux Disease (GERD)

Summary: the purpose of this study was to gather long-term follow-up data on patients treated with the plicator in a previous open-label multi-center study. originally, 64 subjects were treated at seven u.s. sites. a subset of those patients were subsequently reassessed via symptom questionnaires in this long-term (60-month) follow-up analysis. the initial open-label study was completed and officially closed at the completion of 1-year follow-up. this current study was designed to collect long-term follow-up data on previously plicated subjects all of whom were recruited de novo from the original study population. study endpoints were prospectively defined. the primary study objectives were to assess: reduction in gerd symptoms through analysis of the gerd health related quality of life (hrql) questionnaire and the gastrointestinal symptom rating scale (gsrs); reduction in use of gerd medications, and change in overall physical and psychological health as measured by the short form health survey (sf-36).


Eligibility criteria:
inclusion criteria (required prior to original treatment): * history of heartburn or regurgitation for at least 6-months requiring maintenance daily anti-secretory therapy; * esophageal manometry study demonstrating peristaltic amplitude \>35mmhg and les resting pressure \>/=5mmhg; * increased esophageal acid exposure demonstrated through a 24-hour ph study. exclusion criteria (required prior to original treatment): * erosive esophagitis (savary-miller grade iii or iv); * barrett's esophagus; * esophageal stricture; * hiatal hernia \>2cm; * persistent dysphagia, weight loss, esophageal bleeding, vomiting or gas-bloat * esophageal or gastric varices; * use of anticoagulants other than for cardiac prophylaxis * pregnancy

Keywords: gastroesophageal reflux disease (gerd) long-term follow-up (ltfu) endoscopic full-thickness plication plicator
prospective evaluation of blood biomarkers as an aid to diagnostic and treatment in drug-naive patients with depression

Conditions: Depressive Disorder; Bipolar Disorder; Bipolar Depression

Summary: this is an observational (non-interventional) prospective study, carried out in drug-naïve outpatients who start a treatment with escitalopram, fluoxetine, sertraline or quetiapine. five blood samples are collected (i.e. before initiating the drug, and then after 1, 2, 4 and 8 weeks of treatment). it does not affect the choice or the treatment dose. the primary objective of this study is to measure the association between the edit-b® editing signature and response to pharmacological treatment in drug-naïve patients. results of this research could provide an aid to early diagnosis, optimize pharmacological treatment and guide clinical practice towards individualized treatment.


Eligibility criteria:
inclusion criteria: * adult drug-naïve outpatients suffering from depression and/or bipolar disorders who start a pharmacological treatment with escitalopram, fluoxetine, sertraline or quetiapine and who gave his written informed consent to participate in the present study. exclusion criteria: * any patient without capacity of discernment or with harmful use of psychoactive substances
antimicrobial photodynamic therapy on periodontal treatment and salivary status of type 1 diabetes mellitus patients

Conditions: Diabetes Mellitus, Type 1; Periodontal Diseases; Periodontal Pocket

Summary: the aim of this study is to evaluate adjuvant effect of antimicrobial photodynamic therapy in periodontal treatment and salivary status of type 1 diabetes patients.

diabetes mellitus is a risk factor for periodontal disease increasing its prevalence, extension and severity. periodontal disease is considered the sixth complication of diabetes. there is a global epidemic of diabetes, including an increase of type 1 diabetes incidence in younger patients. adjuvant treatments to scaling and root planing as antimicrobial photodynamic therapy show improved clinical outcomes. thus, the aim of this randomized clinical trial is to evaluate adjuvant effect of antimicrobial photodynamic therapy in periodontal treatment and salivary status of type 1 diabetes patients.

Eligibility criteria:
inclusion criteria: * diagnose of type 1 diabetes mellitus * age between 18 to 65 years old * presence of at least one tooth for hemiarch * moderate and severe periodontal disease exclusion criteria: * type 2 diabetes mellitus * total edentulism * smokers * pregnancy * systemic diseases as other endocrine diseases and blood diseases * use of drugs that alter periodontal tissue as phenytoin and cyclosporine
low cost qtc meter for long qt syndrome screening in primary care

Conditions: Long QT Syndrome

Summary: the purpose of this study is to further develop and evaluate a diagnostic procedure suitable for use in an inexpensive diagnostic instrument suitable for screening for long qt syndrome (lqts) in the primary care environment.

the study will involve acquiring ecg data in a cohort of up to 1,000 newborns and infants (500 controls (non-lqts) and 500 lqts newborns and infants) that are being seen in the gonda sl ecg lab (or baldwin building)and enrolled during their appointment for a clinically indicated 12-lead ecg. a second arm of phase ii of this study will include approaching 50 healthy subjects at the baldwin building to seek interest in participation which will consist of (1) 30 second device recording to help further calibrate and test the device for optimal enhancement. these 50 subjects will not be required to have a clinical or research 12-lead ecg as the investigators will be simply testing the efficiency and accuracy of the device. lqts will be studied in order to assess the ability of the lqts screener to accurately detect a patient with established qt prolongation in the context of distinct and varied t wave morphologies the advanced prototype will be placed in the same manner as the device used in phase i of the study by being lightly placed on the child as pictured below. similarly, the investigators will use ultrasound gel to obtain a better reading, if applicable. once completed, a photograph of the torso of the child will be taken from the same views as before (one aerial view and one side view) with neither the head nor the face in the picture. coded ecg-tracings will be transmitted to the app and shared with blue ox health corporation and minnesota health solutions as done previously in phase i. additionally, coded tracings and data from the 12-lead ecg will be shared with blue ox health corporation and minnesota health solutions to aid in comparison to device tracings and optimization of the algorithm. the 12-lead ecg will be obtained from the subject's medical record and coded before being shared with collaborators. study coordinators will also review the patient's medical record to determine whether the participants have been diagnosed with a genetic disease.

Eligibility criteria:
inclusion criteria: * infants (day 0 - 5 years). * long qt syndrome(lqts). * newborns without lqts (controls). * parental willingness to provide informed consent and follow the study protocol. exclusion criteria: * children \> 5 years old. * those with genetically elusive lqts. * infants with congenital heart disease. * infants born \< 32 weeks ega. * patients with a cardiac device implant (pacemaker/icd).
ivus study for sv graft: y-composite vs aortocoronary conduit

Conditions: Coronary Artery Disease; Morphologic Change

Summary: left internal thoracic artery (lita) has been acknowledged as the first graft of choice for coronary artery bypass grafting (cabg). however, it is still not conclusive which one is the best second graft of choice among right internal thoracic artery, radial artery, right gastroepiploic artery, saphenous vein, and etc., as well as its configuration for cabg. in our institution, saphenous vein has been primarily used for the second graft and we have harvested it with 'no touch technique'. we have been demonstrated the excellent long-term patency of this 'no touch saphenous vein' in many studies. however, it is still unknown which configuration is the better strategy for the saphenous vein as a y-composite graft based on the left internal thoracic artery versus an aortocoronary conduit. thus, we aimed to evaluate morphologic change of saphenous vein graft by 1-year intravascular ultrasound (ivus) study and angiographic patency results between y-composite graft and aortocoronary conduit.

the enrolled patient underwent routine sternotomy, and left internal thoracic artery (lita) and saphenous vein (sv) are harvested. after harvest, the patient is randomized to y-composite group or aortocoronary group. for y-composite group, sv is anastomosed to lita as y-composite fashion. then, lita is anastomosed to left anterior descending artery. sv is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posteriori descending artery). for aortocoronary group, lita is anastomosed to left anterior descending artery. then, sv is anastomosed to ascending aorta using proximal anastomosis assist device without clamping the aorta. sv is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posteriori descending artery). after completion of anastomoses, residual portion of distal sv is collected for microscopic evaluation and measurement of intima-media thickness. at the 1-year follow-up, ivus study, in addition to coronary angiography, is performed to evaluate the morphologic changes and measure intima-media thickness of the saphenous vein graft.

Eligibility criteria:
inclusion criteria: * a patient who is going to receive coronary artery bypass grafting * older than 19 years * coronary artery bypass grafting is going to be performed with left internal thoracic artery and saphenous vein graft exclusion criteria: * other concomitant procedures (e.g. valve or aorta surgery) is planned * patients with severe comorbidities which limit the life expectancy of them below 1 year (e.g. terminal cancer) * patients whose left internal thoracic artery or saphenous vein is not available due to the low quality, severe injury, or absence of the graft

Keywords: coronary artery bypass grafting saphenous vein intravascular ultrasound
efficacy of antioxidant therapy compared with enalapril in sickle nephropathy

Conditions: Microalbuminuria; Sickle Cell Nephropathy

Summary: the purpose of this study is to determine whether enalapril or antioxidant therapy (n-acetylcysteine) is effective in reducing microalbuminuria in children with sickle cell disease and and its progression to sickle nephropathy


Eligibility criteria:
inclusion criteria: * homozygous s sickle cell disease * diagnosed by newborn screening * determined to have persistent microalbuminuria * satisfied criteria for microalbuminuria screening * parental consent exclusion criteria: * asymptomatic bacteriuria on screening urine cultures * on hydroxyurea therapy * pre-existing complications of scd which would meet local criteria for hu therapy
brodalumab (amg 827) in rheumatoid arthritis (ra) participants with inadequate response to methotrexate

Conditions: Rheumatoid Arthritis

Summary: study in participants with ra who have an inadequate response to methotrexate.


Eligibility criteria:
inclusion criteria: * active ra for least 6 months * current ra defined as ≥ 6 swollen joints (out of 66 joints examined) and ≥ 8 tender/painful joints (out of 68 joints examined) at screening and baseline (swollen and tender/painful joint count must not include distal interphalangeal joints) and at least 1 of the following at screening: erythrocyte sedimentation rate ≥ 28 mm or c-reactive protein \> 15 mg/l * at least 1 of the following at screening: rheumatoid factor positive or anti-cyclic citrullinated peptide antibody positive * currently taking methotrexate for ≥ 12 weeks and on a stable dose of methotrexate at 15 to 25 mg weekly for ≥ 4 weeks at day -1. exclusion criteria: * prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening * class iv ra * felty's syndrome * presence of serious infection * significant concurrent medical conditions * pregnant or breast feeding * significant laboratory abnormalities * any disease-modifying anti-rheumatic drug (dmard) other than methotrexate within 28 days * leflunomide or live vaccines within 3 months * previous use of any experimental or commercially available biologic dmard

Keywords: autoimmune diseases musculoskeletal diseases joint diseases arthritis connective tissue diseases arthritis, rheumatoid rheumatic diseases
brain cell injury in patients with a first episode of psychosis

Conditions: Psychoses

Summary: patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. this study will compare patients with psychosis to healthy volunteers to determine if there are differences in their blood that reflect oxidative brain cell damage.

preliminary research indicated that impaired antioxidant defense and increased lipid peroxidation is associated with brain changes during the onset of psychosis. oxidative cell injury may contribute to poor outcomes in some patients. this study will define the extent and nature of oxidative cell injury that is associated with psychopathology at the onset of psychosis. participants in this study will be patients at the d. d. eisenhower army medical center who are experiencing a psychotic episode for the first time. patients will be compared with 40 healthy volunteers (control group) matched with patients for age, gender, education, ethnic background, and occupational status. patients and volunteers will have blood tests to determine the level of oxidative cell injury. tests will be performed at onset of psychosis, and after 6 and 12 weeks of neuroleptic drug treatment. medical histories and mri scans will be used to examine the relationship of the laboratory tests to the clinical presentation.

Eligibility criteria:
inclusion criteria * patients must meet clinical diagnostic criteria for psychosis * healthy (control) volunteers must not have any family history of mental illness

Keywords: complementary therapies
brain network connectivity of patients with metabolic diseases

Conditions: Metabolic Disease

Summary: the global prevalence of metabolic diseases, including hypertension, type 2 t2dm mellitus (t2dm), gout and obesity, has risen over the past two decades. brain controls human behavior and metabolism in organisms. it will be very interesting to explore whether there are similarities or relations among different metabolic diseases and how brain might be involved in the progression of different metabolic diseases. we analyzed the pet-ct images and clinical biological markers of 112 cases of hypertension, 56 cases of t2dm, 11 cases of obesity, 14 cases of gout, and 497 cases without the above diseases. standardized uptake value ratios (suvrs) were extracted from different brain regions according to aal brain atlas using spatial-normalization-of-brain-pet-images. partial correlation analysis was used to analyze the correlation of the suvrs of different brain regions with clinical biological markers by controlling sex, age and bmi. brain network metabolic connectivity was analyzed using permutation_ihep software and visualized using brainnet viewer.


Eligibility criteria:
inclusion criteria: * patients who underwent brain pet-ct in sun yat-sen memorial hospital from january 2018 to june 2024 exclusion criteria: * brain lesions, including patients with brain atrophy, cerebral ischemia and trauma, epilepsy, brain tumors, brain trauma, and psychiatric disorders; patients with missing medical history or brain imaging data; patients with tumor.